In this context, inhibitors of LSD1 that mimic the effect of HMG20A are currently in phase IIA clinical trials for the treatment of multiple sclerosis and Alzheimer’s disease (https://www.oryzon.com/en/news/2019). Here, HMG20A is linked to early-onset autosomal dominant Alzheimer disease.